Interims confirm turnaround at Flamel

- Last updated on GMT

Related tags: United states dollar, Flamel

French drug delivery specialist Flamel posts a healthy rise in
revenues in the second quarter, boosted by milestone payments from
GSK and Servier.

French drug delivery specialist Flamel Technologies saw its second quarter revenues rise 14 per cent to $5 million (€4.4m) over the same period of 2002, boosted by milestone payments from GlaxoSmithKline and Servier.

Flamel​ is developing new versions of undisclosed GSK and Servier drugs, as well as a new sachet formulation of GSK's Augmentin (amoxicillin/clavulanate) antibiotic, using its Micropump controlled release technology for oral delivery of small-molecule drugs. At present Flamel makes most of its money from licence and research revenue, and the company's activities in contract manufacturing and services brought in just $900,000 in the last quarter.

Flamel saw its net loss climb to $1.7 million in the second quarter, compared to just $68,000 a year earlier, as the cost of developing its long-acting Basulin (insulin) product swelled R&D spending by 74 per cent to $4.7 million. Currency factors also played a role in this, according to Flamel, which noted there was an increase of 23 per cent in the value of the Euro against the US dollar during the 12-month period.

Despite posting a loss, the French company has undergone something of a renaissance in the last few months after a difficult period in early 2002 when its former partner for Basulin, Novo Nordisk, pulled out of the project.

Basulin is based on its Medusa protein delivery system and in a recent study exhibited a pharmacokinetic profile that was similar to Aventis' recently-introduced long-acting insulin Lantus (insulin glargine), which achieved sales growth of 90 per cent in the first half of this year to reach €199 million.

Flamel is confident that it can position Basulin as a Lantus rival, but also that the development of the drug will raise the profile of its Medusa technology, which can be used to improve delivery of therapeutic proteins (a market currently estimated at around $27 billion).

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Follow us


View more